Opinion|Videos|November 4, 2024
Academic Perspectives for Evaluating, Identifying, and Managing CRS
Panelists discuss the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.
Advertisement
Video content above is prompted by the following:
- What are the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS)?
- Pretreatment phase
- Patient education and monitoring
- Treatment location
- Premedications
- Management of CRS
- Dose modifications and retreatment
- Community oncology perspective
Advertisement
Related to this article
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.
Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
3
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5